Alnylam Pharmaceuticals, Inc. (ALNY) — ESG & Values Scores

Environment story

Alnylam discloses minimal environmental data in available filings. Scope 1, Scope 2, and Scope 3 emissions are not disclosed. The company does not publicize a net-zero target year or formal climate commitments. No evidence of decarbonization infrastructure investments is provided. Risk factors mention potential exposure to tariff-related supply-chain disruptions and cybersecurity threats to manufacturing, but no environmental controversies, toxic waste, or water consumption incidents are disclosed in reviewed materials. The company's pharmaceutical manufacturing relies on third-party CMOs; manufacturing facility expansion is planned at Norton, Massachusetts but environmental impact mitigation is not detailed.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Norton Manufacturing Facility Expansion

In December 2025, company announced planned expansion of Norton, Massachusetts manufacturing facility to increase capacity and reduce production costs.

Operational efficiency gain; no explicit decarbonization or renewable energy commitment disclosed.

Social story

Alnylam discloses a CEO-to-median-worker pay ratio of 48:1 for 2025, well below the 200:1 threshold. The company has expanded workforce significantly in 2025 with high recruitment activity to support commercial launches and R&D. No documented union-suppression activities, major strikes, or labor disputes are disclosed. Leadership diversity metrics are not explicitly quantified in proxy materials, though board includes female directors (Dr. Greenstreet, Dr. Hamburg, Ms. Schulman). The company emphasizes People and Culture strategy and diversity, equity, and inclusion in clinical trials. Supply-chain audits and human-rights hazard mitigation for cobalt, lithium, or other conflict minerals are not disclosed. No major labor controversies identified in available sources.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

People and Culture Strategy 2026 Roll-Out

Company plans 2026 implementation of updated People and Culture strategy focused on talent retention and organizational development.

Intended to support employee engagement and retention during growth phase.
Diversity, Equity and Inclusion in Clinical Trials

Company states ongoing efforts to increase DEI representation in clinical trials.

Enhances representation in research cohorts; supports inclusive product development.
Diversity in Board and Leadership

Board includes multiple female directors and emphasizes diversity of age, education, background, and professional experience.

Board composition reflects diverse viewpoints; commitment to inclusive governance.

Governance story

Alnylam operates with a single-class common stock structure (no dual-class voting rights identified). Board independence is not explicitly stated as a percentage in proxy materials, but the board includes multiple independent directors across committees (nominating, audit, compensation, science/technology). Board composition reflects a mix of industry expertise, medical/scientific backgrounds, and business acumen. No active antitrust proceedings, consumer-safety litigations, or SEC consent decrees are disclosed in reviewed materials. Lobbying expenditures targeting climate deregulation or consumer-protection rollbacks are not disclosed. The company engages in stockholder engagement activities and has implemented risk-oversight procedures for executive compensation. Cybersecurity risks are acknowledged as material operational risks. CEO Dr. Greenstreet has a written employment agreement with change-in-control provisions; other NEOs have change-in-control agreements.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Board Self-Evaluation and Governance Alignment

Nominating and Corporate Governance Committee facilitates regular board self-evaluation aligned to board best practices, focusing on structure, process, committee performance, and culture.

Supports ongoing board effectiveness and governance maturity.
Compensation Risk Oversight

PC&C Committee engaged independent compensation consultant (Pay Governance) in February 2025 to assess whether compensation policies create excessive risk; consultant concluded no excessive or inappropriate risk-taking.

Governance safeguard; validates alignment of incentive design with stakeholder interests.
Majority Voting Policy for Directors

Non-contested director elections require affirmative vote of majority of votes cast; directors receiving more votes against than for must tender resignation.

Ensures director accountability and stockholder alignment.
Stockholder Engagement Program

Board and management conducted regular engagement with stockholders in 2025; feedback conveyed to board and committees for strategic consideration.

Enhanced transparency and responsiveness to shareholder concerns.
Cybersecurity Risk Governance

Nominating and Corporate Governance Committee monitors risks associated with information systems and cybersecurity; management implements information technology policies.

Proactive identification and mitigation of data security threats.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Alnylam Pharmaceuticals, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Alnylam Pharmaceuticals, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)